S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:BDSX

Biodesix Stock Forecast, Price & News

$5.26
-0.68 (-11.45%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.21
$6.00
50-Day Range
$5.26
$8.97
52-Week Range
$5.21
$31.99
Volume
57,361 shs
Average Volume
95,340 shs
Market Capitalization
$142.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.98
30 days | 90 days | 365 days | Advanced Chart
Receive BDSX News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.


Biodesix logo

About Biodesix

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Headlines

Biodesix, Inc. (NASDAQ:BDSX) Director Buys $390,000.00 in Stock
November 23, 2021 |  americanbankingnews.com
Biodesix (NASDAQ:BDSX) Lowered to Equal Weight at Morgan Stanley
November 17, 2021 |  americanbankingnews.com
Biodesix (NASDAQ:BDSX) PT Lowered to $22.00
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDSX
Phone
N/A
Fax
N/A
Employees
200
Year Founded
N/A

Sales & Book Value

Annual Sales
$45.56 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,592,000
Market Cap
$142.13 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

2.42 out of 5 stars

Medical Sector

179th out of 1,388 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Biodesix (NASDAQ:BDSX) Frequently Asked Questions

Is Biodesix a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biodesix stock.
View analyst ratings for Biodesix
or view top-rated stocks.

When is Biodesix's next earnings date?

Biodesix is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Biodesix
.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.09. During the same period in the prior year, the company earned ($31.93) EPS.
View Biodesix's earnings history
.

What price target have analysts set for BDSX?

3 analysts have issued 1 year target prices for Biodesix's stock. Their forecasts range from $11.00 to $22.00. On average, they anticipate Biodesix's share price to reach $18.33 in the next year. This suggests a possible upside of 248.5% from the stock's current price.
View analysts' price targets for Biodesix
or view top-rated stocks among Wall Street analysts.

Who are Biodesix's key executives?

Biodesix's management team includes the following people:
  • Mr. Scott Hutton, Pres, CEO & Director (Age 49, Pay $531.88k) (LinkedIn Profile)
  • Ms. Robin Harper Cowie, CFO, Sec. & Treasurer (Age 41, Pay $375.24k) (LinkedIn Profile)
  • Mr. Kieran O'Kane, Chief Commercial Officer (Age 44, Pay $310.06k)
  • Dr. Heinrich Röder, Founder & CTO
  • Mr. Robert E. Cawthorn, Founder & Director Emeritus (Age 86)
  • Mr. Ryan H. Siurek, Chief Accounting Officer (Age 49)
  • Mr. Jeffrey A. Bojar, VP of Legal and Regulatory Affairs
  • Mr. Matt Stauffer, VP of Sales
  • Dr. Paul J. Beresford, Chief Bus. Officer
  • Dr. Gary Anthony Pestano, Chief Devel. Officer (Age 54)

When did Biodesix IPO?

(BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Biodesix's stock symbol?

Biodesix trades on the NASDAQ under the ticker symbol "BDSX."

Who are Biodesix's major shareholders?

Biodesix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.12%), Oracle Investment Management Inc. (0.67%), Geode Capital Management LLC (0.56%), Morgan Stanley (0.40%), Avidian Wealth Solutions LLC (0.19%) and Citadel Advisors LLC (0.18%). Company insiders that own Biodesix stock include Jack W Schuler, John Patience, Robin Harper Cowie and Scott Hutton.
View institutional ownership trends for Biodesix
.

Which major investors are selling Biodesix stock?

BDSX stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., California State Teachers Retirement System, Citadel Advisors LLC, and BlackRock Inc..
View insider buying and selling activity for Biodesix
or view top insider-selling stocks.

Which major investors are buying Biodesix stock?

BDSX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Two Sigma Advisers LP, Avidian Wealth Solutions LLC, Trexquant Investment LP, and Geode Capital Management LLC. Company insiders that have bought Biodesix stock in the last two years include Jack W Schuler, John Patience, Robin Harper Cowie, and Scott Hutton.
View insider buying and selling activity for Biodesix
or or view top insider-buying stocks.

How do I buy shares of Biodesix?

Shares of BDSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biodesix's stock price today?

One share of BDSX stock can currently be purchased for approximately $5.26.

How much money does Biodesix make?

Biodesix has a market capitalization of $142.13 million and generates $45.56 million in revenue each year.

How many employees does Biodesix have?

Biodesix employs 200 workers across the globe.

What is Biodesix's official website?

The official website for Biodesix is www.biodesix.com.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.